On Friday, Health Canada added 4 cultivation licenses, bringing the total licenses awarded to date to 109. The agency added BC-based Good Buds Company, which was the first licensed producer (LP) to receive a cultivation and production license simultaneously, Quebec-based Medican Organic, Ontario-based Toronto Herbal Remedies and a second site license for WeedMD (TSXV: WMD) (OTC: WDDMF), which is in the process of merging with Hiku Brands (CSE: HIKU) (OTC: DJACF), a 14-acre greenhouse in Ontario.

Many of the 109 LP licenses issued to date are now held by publicly-traded companies, with several holding multiple licenses, including Canopy Growth (10), Aurora Cannabis (5), Emerald Health (3.5), Maricann (3), Aphria (2), Cronos Group (2), MedReleaf (2), Newstrike (2), RedeCan Pharm (2), Tilray (2), WeedMD (2), Zenabis (2) and Invictus MD Strategies (1.5).

As of June 8th, there were 33 publicly-traded LPs, all of which are included in the Canadian Cannabis LP Index, which is down 10% so far in 2018 but has increased by over 803% since its inception on 12/31/15. Several LPs are in the process of going public, including two expected to begin trading this week, 48North and James E. Wagner Cultivation Corporation (JWC).

48North

48North, the parent of Delshen Therapeutics in Northern Ontario, has a licensed indoor facility of 40K sq. ft.that it projects can produce 2.5 million grams annually, though it isn’t yet approved for selling. It has licensed genetics from Maripharm B.V. in the Netherlands and is evaluating an expansion on its 800 acres in Kirkland Lake to build a 200K sq. ft. facility in two phases that would add 40 million grams to its annual production capacity. We interviewed CEO Alison Gordon in April, where she discussed the company and its focus on the development of a health and wellness brand for women. The company is expected to begin trading on the TSX Venture with the symbol “NRTH” this week. Investors seeking more information can consult the filing statement.

JWC

JWC, which is licensed to cultivate and to sell, is based in Ontario and produces aeroponically grown cannabis, using its GrowthStorm cultivation platform. Its current facility is 15K sq. ft. and produces 1.5 million grams annually in 7 grow rooms, and the company is targeting 28.5 million grams in its second facility under development, a 345K sq. ft. retrofit that it expects to complete in the second quarter of 2019. The company has a strategic relationship with Canopy Growth through its CraftGrow and Tweed Main Street programs, its genetics and its extraction infrastructure and Canopy Rivers, which provides it with capital and owns 13.7% of the company on a fully-diluted basis. The company is expected to begin trading on the TSX Venture with the symbol “JWCA” on June 11th. Investors seeking more information can consult the filing statement.

We have edited this article to reflect that 48North will be trading on the TSX Venture not the CSE and to reflect that Emerald Health has 3.5 licenses (not 2.5)

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Exclusive article by Alan Brochstein, CFA Facebook | LinkedIn | Email Based in Houston, Alan leverages his experience as founder of online communities 420 Investor , the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures , he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha , where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter